Welcome to our dedicated page for Viracta Therapeutics news (Ticker: $VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viracta Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viracta Therapeutics's position in the market.
Rhea-AI Summary
Viracta Therapeutics reports positive topline results from Stage 1 of the NAVAL-1 trial in patients with relapsed or refractory EBV+ PTCL. Nana-val combination therapy shows an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population, with manageable safety profile. Data presented at 2024 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.17%
Tags
-
Rhea-AI Summary
Viracta Therapeutics, Inc. (VIRX) announces topline Stage 1 data from NAVAL-1 trial of Nana-val in EBV+ peripheral T-cell lymphoma patients will be presented at a medical congress. The presentation will focus on the 'Kick and Kill' mechanism of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
-
Rhea-AI Summary
LENZ Therapeutics, a late clinical-stage biopharmaceutical company, is set to debut on Nasdaq under the ticker symbol 'LENZ'. The company is advancing late-stage assets for presbyopia treatment, with topline data from Phase 3 CLARITY trials expected in April 2024. LENZ boasts a strong balance sheet with approximately $210 million in cash and cash equivalents, including $53.5 million from a concurrent PIPE financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
409.43%
Tags
Rhea-AI Summary
Viracta Therapeutics, Inc. (VIRX) completes Stage 2 enrollment in NAVAL-1 trial of Nana-val for EBV+ lymphoma, expects topline results in Q2 2024. Strengthened balance sheet with $5.0 million non-dilutive proceeds, extending cash runway. Clinical trial updates, business developments, and financial results detailed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.98%
Tags
-
Rhea-AI Summary
Viracta Therapeutics, Inc. completes Stage 2 enrollment for Nana-val in treating EBV-associated cancers. Topline results expected in Q2 and Q3 of 2024. FDA meeting planned for mid-2024 for potential accelerated approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.87%
Tags
-
News
Rhea-AI Summary
Viracta Therapeutics, Inc. (VIRX) announced the participation of its President and CEO, Mark Rothera, and Chief Medical Officer, Darrel P. Cohen, in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The webcast will be available on the company's website. The company focuses on precision oncology for virus-associated cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.68%
Tags
Rhea-AI Summary
Viracta Therapeutics, Inc. (VIRX) provided a clinical update on Nana-val's clinical development in 2024, focusing on patients with relapsed or refractory EBV+ peripheral T-cell lymphoma and advanced EBV+ solid tumors. The company aims to complete enrollment of Stage 2 for the R/R EBV+ PTCL cohort in Q1 2024 and engage with the FDA on potential accelerated approval pathway by mid-2024. Additionally, they plan to determine the recommended Phase 2 dose and initiate Phase 2 in 2024 for patients with advanced EBV+ solid tumors. The company also highlighted recent clinical trial updates, including the completion of enrollment of Stage 1 in the R/R EBV+ PTCL cohort, initiation of the sixth dose cohort of patients with recurrent or metastatic EBV+ nasopharyngeal carcinoma, and the FDA granting an orphan drug designation to Nana-val for the treatment of NPC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
-
Rhea-AI Summary
Viracta Therapeutics, a precision oncology company (Nasdaq: VIRX), received the first orphan drug designation (ODD) for Nana-val in EBV+ solid tumors. This is the seventh ODD for Nana-val globally and the fifth granted by the FDA. The FDA granted ODD to Nana-val for the treatment of nasopharyngeal carcinoma (NPC), marking its first ODD in EBV+ solid tumors and outside of EBV-associated lymphomas. The company's President and CEO, Mark Rothera, expressed optimism about the interim data from the Phase 1b/2 study of Nana-val in patients with recurrent or metastatic EBV-positive nasopharyngeal carcinoma. The ODD provides various benefits, including potential market exclusivity, tax credits, reduced fees, and expedited drug development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
-
Rhea-AI Summary
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced encouraging Phase 1b/2 clinical trial data of Nana-val in patients with recurrent or metastatic Epstein-Barr virus-positive nasopharyngeal carcinoma (NPC) at the ESMO Asia Congress. The study showed two ongoing confirmed partial responses at higher dose levels, supporting the advancement and dose escalation of the study. Enrollment for the sixth dose cohort is underway, with plans to initiate a recommended Phase 2 dose-optimization cohort in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
Rhea-AI Summary
VIRX: Viracta Therapeutics Reports Positive Clinical Data from NAVAL-1 Trial, Plans to Engage with FDA in 2024 for Accelerated Approval
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.81%
Tags
Viracta Therapeutics, Inc.
Nasdaq:VIRX
VIRX Rankings
VIRX Stock Data
32.99M
24.55M
2.88%
52.8%
1.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
CARDIFF
About VIRX
viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus, and will pursue opportunities to address other serious virus-associated disease.